Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline)
with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
Not exact matches
The Federal Joint Committee (G - BA) specified two appropriate comparator therapies according to the approval status: Treatment - naive patients, i.e. patients who had not been treated for HIV before, were to receive
efavirenz in combination
with tenofovir and emtricitabine or in combination
with abacavir and lamivudine.
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA - 824
with concomitant lopinavir - ritonavir,
efavirenz, or rifampin.